Elevated reticulocyte count – a clue to the diagnosis of haemolytic-uraemic syndrome (HUS) associated with gemcitabine therapy for metastatic duodenal papillary carcinoma: a case report

作者: S Serke , H Riess , H Oettle , D Huhn

DOI: 10.1038/SJ.BJC.6690242

关键词:

摘要: In adults, the haemolytic-uraemic syndrome (HUS) is associated with probable causative factors in minority of all cases. Cytotoxic drugs are one these potential agents. Although metastatic cancer by itself a recognized risk-factor for development HUS, therapy mitomycin-C, cis-platinum, and bleomycin carries significant, albeit extremely small, risk compared other cytotoxic drugs. Gemcitabine novel drug promising activity against pancreatic adenocarcinoma. We reporting on patient duodenal papillary carcinoma developing HUS while weekly gemcitabine therapy. The presenting features this were non-cardiac pulmonary oedema, renal failure, thrombocytopenia haemolytic anaemia. diagnosis was made day admission to institution. Upon aggressive therapy, including single haemodialysis five plasmaphereses, recovered uneventfully, modestly elevated creatinine-values as remnant acute illness. Re-exposure 6 months after episode instituted progressive carcinoma, thus far has not caused another HUS.

参考文章(21)
Nordström B, Strang P, Microangiopathic hemolytic anemias (MAHA) in cancer. A case report and review Anticancer Research. ,vol. 13, pp. 1845- 1849 ,(1993)
E. C. Kovalik, D. N. Howell, G. Macik, S. R. Smith, P. J. Conlon, The renal manifestations and outcome of thrombotic thrombocytopenic purpura/hemolytic uremic syndrome in adults. Nephrology Dialysis Transplantation. ,vol. 10, pp. 1189- 1193 ,(1995)
H Anderson, B Lund, F Bach, N Thatcher, J Walling, H H Hansen, Single-agent activity of weekly gemcitabine in advanced non-small-cell lung cancer: a phase II study. Journal of Clinical Oncology. ,vol. 12, pp. 1821- 1826 ,(1994) , 10.1200/JCO.1994.12.9.1821
M. Dobbie, S. Hofer, M. Oberholzer, R. Herrmann, Veno-occlusive disease of the liver induced by gemcitabine Annals of Oncology. ,vol. 9, pp. 681- 681 ,(1998) , 10.1023/A:1008225930573
M. Furlan, Von Willebrand factor: molecular size and functional activity Annals of Hematology. ,vol. 72, pp. 341- 348 ,(1996) , 10.1007/S002770050184
Z. R. Zeigler, C. S. Rosenfeld, D. F. Andrews, J. Nemunaitis, J. M. Raymond, R. K. Shadduck, R. E. Kramer, J. F. Gryn, P. B. Rintels, E. C. Besa, J. N. George, Plasma von Willebrand factor antigen (vWF:AG) and thrombomodulin (TM) levels in adult thrombotic thrombocytopenic purpura/hemolytic uremic syndromes (TTP/HUS) and bone marrow transplant‐associated thrombotic microangiopathy (BMT‐TM) American Journal of Hematology. ,vol. 53, pp. 213- 220 ,(1996) , 10.1002/(SICI)1096-8652(199612)53:4<213::AID-AJH1>3.0.CO;2-0
Yvoty A. S. Sens, Luiz A. Miorin, HÉLio G. C. Silva, Denise M.A.C Malheiros, Dino M. Filho, Pedro Jabur, Acute renal failure due to hemolytic uremic syndrome in adult patients. Renal Failure. ,vol. 19, pp. 279- 282 ,(1997) , 10.3109/08860229709026289
Maurizio Tonato, Anna Maria Mosconi, Christophe Martin, Safety profile of gemcitabine. Anti-Cancer Drugs. ,vol. 6, pp. 27- 32 ,(1995) , 10.1097/00001813-199512006-00005
J. Verwey, J. De Vries, H.M. Pinedo, Mitomycin C-induced renal toxicity, a dose-dependent side effect? European Journal of Cancer and Clinical Oncology. ,vol. 23, pp. 195- 199 ,(1987) , 10.1016/0277-5379(87)90014-9